EDGM
Edgemode, Inc.
$0.001500
0.00%
No data for this timeframe.
Vol
SEC Reports1
Recent Activity
May 5, 2026
Insider
Kiero-Watson Simon Scott was granted 10,000,000 shares
Director
Mar 23, 2026
Insider
Mora Jose Antonio was granted 400,000,000 shares
Director of Subsidiary @ $0.006500 ($2.6M)
Mar 4, 2026
SEC
Edgemode, Inc. raised $130,000 in net proceeds through a $150,000 convertible promissory note issued to an accredited in
8-K — Impact 7/10
Feb 10, 2026
Insider
Faulkner Charles Thomas was granted 350,000,000 shares
Chief Executive Officer
Recent Insider Trades
| Date | Insider | Type | Value |
|---|---|---|---|
| May 5, 2026 | Kiero-Watson Simon | A | $0.00 |
| Mar 23, 2026 | Mora Jose | A | $2.6M |
| Feb 10, 2026 | Faulkner Charles | A | $0.00 |
| Feb 10, 2026 | Wajcenberg Simon | A | $0.00 |
| Jan 27, 2026 | Mora Jose | D | $0.00 |
No institutional holding data available yet. Data is sourced from 13F filings which are filed quarterly.
4 unique insiders with 6 transactions. Net insider value: $0.00 ($0.00 bought, $0.00 sold).
Insider Transactions
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| May 5, 2026 | Kiero-Watson Simon Scott | Director | AWARD | 10,000,000 | — | — |
| Mar 23, 2026 | Mora Jose Antonio | Director of Subsidiary | AWARD | 400,000,000 | $0.006500 | $2.6M |
| Feb 10, 2026 | Faulkner Charles Thomas | Chief Executive Officer | AWARD | 350,000,000 | — | — |
| Feb 10, 2026 | Wajcenberg Simon Enrico | Chief Financial Officer | AWARD | 350,000,000 | — | — |
| Jan 27, 2026 | Mora Jose Antonio | Director of Subsidiary | D | 150,000,000 | — | — |
| Jan 22, 2026 | Mora Jose Antonio | Director of Subsidiary | D | 250,000,000 | — | — |
1 SEC filing reports analyzed. Sentiment: 0 bullish, 1 bearish, 0 mixed, 0 neutral. Avg impact: 7.0/10.
No press releases analyzed yet. Press releases are collected from GlobeNewsWire and analyzed by the LLM pipeline.
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q | $0.00 | $0.00 | $0.00 | — | — | — | $0.0B | — | — |
| Next Q | $0.00 | $0.00 | $0.00 | — | — | — | $0.0B | — | — |
| Current FY | $0.00 | $0.00 | $0.00 | — | — | — | $0.0B | — | — |
| Next FY | $0.00 | $0.00 | $0.00 | — | — | — | $0.0B | — | — |
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
No Reddit sentiment data available yet. Sentiment is analyzed from Reddit investment communities on a rolling basis.
No events recorded for this ticker. Events include FDA actions, clinical trials, enforcement actions, and market-moving developments.